To understand the key launch trends in 2024, GlobalData reviewed a sample of innovative drugs that were both approved and ...

The clinical course of GERD is benign in most patients in Asia. The risk of progression from non-erosive reflux disease to erosive esophagitis is low, and treatment response to a conventional dose ...

HK inno.N secures patent rights for K-Cab until 2031 after court victory HK inno.N achieves milestone in exclusive patent ...

Background: A lack of published data remains on factors associated with the treatment response to proton pump inhibitors (PPI) in patients with non-erosive reflux disease (NERD). Methods ...

This came after Dr. Reddy's Lab presented the proposal for grant of permission to manufacture and market Esomeprazole Gastro ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...

LA grades C and D are considered severe GERD. Treatment of EE With Proton Pump Inhibitors Nonsevere GERD can often be managed with lifestyle modifications and medication, whereas patients with more ...

pylori eradication to reduce the risk of duodenal ulcer recurrence: each medication twice daily for 10 days; Maintenance of Healing of Erosive Esophagitis (EE): once daily; Gastroesophageal Reflux ...